Tag results:

fibronectin

Long Noncoding RNA ANRIL Up-Regulates CCND1 via Sponging miR-98-5p to Promote TGF-β1-Induced Human Airway Smooth Muscle Cell Proliferation, Migration, and Extracellular Matrix Deposition

[Kaohsiung Journal of Medical Sciences] Scientists deciphered the role of the lncRNA antisense noncoding RNA in the INK4 locus in airway smooth muscle cell proliferation, migration and extracellular matrix deposition.

NGM Bio Announces Initiation of Phase I/Ib Clinical Trial of NGM831 for the Treatment of Patients with Advanced Solid Tumors

[NGM Biopharmaceuticals, Inc.] NGM Biopharmaceuticals, Inc. announced it has dosed the first patient in a Phase I/Ib clinical trial of NGM831 for the treatment of patients with advanced solid tumors.The trial expects to enroll adult patients with multiple tumor types, including pancreatic cancer, breast cancer and prostate cancer.

NGM Bio Announces Initiation of Phase 1/1b Clinical Trial of NGM831 for the Treatment of Patients with Advanced Solid Tumors

[NGM Biopharmaceuticals, Inc.] NGM Biopharmaceuticals, Inc. announced it has dosed the first patient in a Phase I/Ib clinical trial of NGM831, an antagonist antibody product candidate designed to block the interaction of ILT3 with fibronectin, a key component of the tumor stroma, for the treatment of patients with advanced solid tumors.

Spidroin Striped Micropattern Promotes Chondrogenic Differentiation of Human Wharton’s Jelly Mesenchymal Stem Cells

[Scientific Reports] Scientists directed human Wharton's jelly-MSCs chondrogenesis using micropattern made of spidroin bioink as opposed to fibronectin that often was used as the gold standard.

Platelets Drive Fibronectin Fibrillogenesis Using Integrin αIIbβ3

[Science Advances] In vitro 3D superresolution microscopy complemented by biophysical and biochemical methods revealed fundamental insights into how platelet contractility drove fibronectin fibrillogenesis.

Biohaven Licenses Taldefgrobep Alfa, a Phase III-Ready Anti-Myostatin Adnectin for Spinal Muscular Atrophy (SMA), from Bristol Myers Squibb

[Biohaven Pharmaceutical Holding Company Ltd.] Biohaven Pharmaceutical Holding Company Ltd. announced that it entered into a license agreement with Bristol Myers Squibb for the development and commercialization rights to taldefgrobep alfa, a novel, Phase III-ready anti-myostatin adnectin.

Popular